Letrozole tablets is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
The effectiveness of Letrozole in early breast cancer is based on an analysis of disease-free survival in patients treated for a median of 24 months and followed for a median of 26 months. Follow up analyses will determine long-term outcomes for both safety and efficacy.
Letrozole is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of Letrozole in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated for a median of 24 months. Further data will be required to determine long-term outcome.
Letrozole is indicated for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Letrozole is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Box contains Five Blister Strips of 5 Tablets